

# **IML LARGE-CAP WEBINAR, NOVEMBER 19, 2024**

In the November 2024 large cap webinar IML portfolio managers Hugh Giddy and Daniel Moore analysed the recent performance of the Australian stock market and IML's large cap portfolios. Here are the main points from the webinar:

### Market performance and outlook

The recent strength in equity markets has been characterised by a narrow focus on specific sectors, particularly technology and banking. This concentration has been driven largely by speculative investments, with investors showing a willingness to overlook traditional measures of value in pursuit of chasing higher returns. Despite this environment, we have maintained our commitment to our investment philosophy, focusing on quality business that represent long-term value over short-term popular themes. The IML Investment Team is disappointed by the recent performance but remains confident that their disciplined approach will benefit investors over the long term.

## Sector insights

The Australian banking sector has been a significant contributor to index returns, accounting for roughly half of the market's rise. However, the IML Team remains cautious of this sector due to its high valuations and relatively flat earnings growth and notes that the earnings performance of banks has not warranted their current high valuations. They have been underweight in banks, a position that has been to their detriment in the past year. The speculative nature of technology stocks and cryptocurrencies also warrants caution, as these sectors have seen valuations soar, driven by optimism rather than fundamental earnings growth.

#### Global context

Globally, rising bond yields and diminishing equity risk premiums in both the US and Australia signal heightened market optimism. The equity risk premium, which measures the extra return investors demand for choosing equities over bonds, has reached historically low levels, indicating a lack of risk pricing in the markets. This environment of high optimism suggests that investors are largely ignoring potential risks, a scenario that IML believes calls for a more cautious investment approach. They advise against investing in overvalued popular themes and fads, recommending instead a focus on fundamentals and value.

# Stock highlights

Hugh and Daniel discussed several high-quality stocks they believe offer strong investment potential:

- **Sigma Healthcare**: The company has benefited from its acquisition of Chemist Warehouse, with the approval of this transaction by the ACCC leading to a significant increase in its share price. Despite this, they have been strategically reducing their position due to high valuations that factor in substantial synergies.
- Medibank Private: As the leading private health insurer in Australia, Medibank Private
  continues to show good growth potential. It has effectively managed costs and improved
  customer satisfaction, positioning it well within an industry facing positive demographic trends
  and government incentives.
- Viva Energy: They see Viva Energy as a compelling opportunity, with its integrated refining
  and retail operations benefiting from a changed industry landscape post-COVID. The
  company's refining operations are now supported by government guarantees, and its
  acquisition of On The Run Retail (OTR) is expected to significantly enhance its retail
  profitability.

In conclusion, the IML Investment Team recommends a prudent investment stance amidst current market exuberance. They remain focused on identifying undervalued, high-quality companies that are well-positioned to weather potential market downturns. By sticking to their disciplined investment philosophy, they aim to deliver long-term value and income for their investors, even in an environment characterised by high optimism and speculative activity.

#### Disclaimer

This presentation (the material) has been prepared and distributed by Natixis Investment Managers Australia Pty Limited (NIMA) AFSL 246830 and may include information provided by third parties, including Investors Mutual Limited (IML) AFSL 229988 who is the Responsible Entity of the IML Funds (www.iml.com.au/funds), including the Loomis Sayles Global Equity Fund (www.loomissayles.com.au); and the Vaughan Nelson Global Equity SMID Fund (www.VaughanNelson.com.au) (the 'Funds'). Although NIMA believe that the material is correct, no warranty of accuracy, reliability or completeness is given, including for information provided by third parties, except for liability under statute which cannot be excluded, and does not accept any liability for any loss, damage or consequence, whether caused by our own negligence or not, resulting directly or indirectly from this presentation.

This information is not personal advice. The material has been prepared without taking account of your objectives, financial situation or needs. Statements of opinion are those of IML unless otherwise attributed. Except where specifically attributed to another source, all figures are based on IML research and analysis. Any investment metrics such as prospective P/E ratios and earnings forecasts referred to in this presentation constitute estimates which have been calculated by IML's investment team based on IML's investment processes and research. Applications can only be made using the current application form for the relevant Fund, or through IDPS products that include these Funds. The Product Disclosure Statements and the relevant Target Market Determinations can be obtained by contacting Investors Mutual or at www.iml.com.au; or www.loomissayles.com.au; or www.vaughannelson.com.au, as the case may be. Potential investors should consider the relevant Product Disclosure Statement, Target Market Determination, and Investment Guide, where applicable, before deciding whether to invest, or continuing to invest in the Funds.

Past performance is not a reliable indicator of future performance. Returns can be volatile, reflecting rises and falls in the value of underlying investments. Potential investors should seek independent advice as to the suitability of the Fund to their investment needs. The fact that shares in a particular company may have been mentioned should not be interpreted as a recommendation to either buy, sell or hold that stock. Any commentary about specific securities is within the context of the investment strategy for the given portfolio.